# CNO Financial Group, Inc.: Form 10-Q for the period ended Jun 30, 2025

- Company: [CNO Financial Group, Inc.](/companies/cno.md) (CIK 1224608)
- Form: 10-Q
- Filed: 2025-08-06
- Accepted by EDGAR: Aug 6, 2025, 16:46 ET
- Period: 2025-06-30
- Accession: 0001224608-25-000045
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1224608/000122460825000045/cno-20250630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1224608/000122460825000045/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-04-01 to 2025-06-30 | $1.15bn | us-gaap:Revenues |
| Revenue | 6 months, 2025-01-01 to 2025-06-30 | $2.16bn | us-gaap:Revenues |
| Operating income | 3 months, 2025-04-01 to 2025-06-30 | $112.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2025-01-01 to 2025-06-30 | $216.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-04-01 to 2025-06-30 | $59.1m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2025-01-01 to 2025-06-30 | $121.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2025-04-01 to 2025-06-30 | $26.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2025-01-01 to 2025-06-30 | $32.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-04-01 to 2025-06-30 | $91.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2025-01-01 to 2025-06-30 | $113.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2025-04-01 to 2025-06-30 | $0.91 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2025-01-01 to 2025-06-30 | $1.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2025-04-01 to 2025-06-30 | $0.93 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2025-01-01 to 2025-06-30 | $1.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2025-04-01 to 2025-06-30 | 100,386,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2025-01-01 to 2025-06-30 | 101,728,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2025-01-01 to 2025-06-30 | $282.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 6 months, 2025-01-01 to 2025-06-30 | $33.6m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2025-01-01 to 2025-06-30 | $210.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Total assets | at 2025-06-30 | $37.33bn | us-gaap:Assets |
| Total liabilities | at 2025-06-30 | $34.81bn | us-gaap:Liabilities |
| Shareholders' equity | at 2025-06-30 | $2.52bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 104,670 characters.

In this section, we review the consolidated financial condition of CNO as of June 30, 2025, and its consolidated results of operations for the six months ended June 30, 2025 and 2024, and, where appropriate, factors that may affect future financial performance. Please read this discussion in conjunction with the accompanying consolidated financial statements and notes. Results for interim periods are not necessarily indicative of the results that may be expected for a full year.

### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our statements, trend analyses and other information contained in this report and elsewhere (such as in filings by CNO with the SEC, press releases, presentations by CNO or its management or oral statements) relative to markets for CNO's products and trends in CNO's operations or financial results, as well as other statements, contain forward-looking statements within the meaning of the federal securities laws and the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by the use of terms such as "anticipate," "believe," "plan," "estimate," "expect," "project," "intend," "may," "will," "would," "contemplate," "possible," "attempt," "seek," "should," "could," "goal," "target," "on track," "comfortable with," "optimistic," "guidance," "outlook," "sustainable," "repeatable," "confident in" and similar words, although some forward-looking statements are expressed differently. You should consider statements that contain these words carefully because they describe our expectations, plans, strategies and goals and our beliefs concerning future business conditions, our results of operations, financial position, and our business outlook or they state other "forward-looking" information based on currently available information. The "Risk Factors" section of our 2024 Annual Report on Form 10-K provides examples of risks, uncertainties and events that could cause our actual results to differ materially from the expectations expressed in our forward-looking statements. Assumptions and other important factors that could cause our actual results to differ materially from those anticipated in our forward-looking statements include, among other things:

- general economic, market and political conditions and uncertainties, including the performance and fluctuations of the financial markets (including the impact of inflation, market volatility, the impact of tariffs, changes in tax laws, changes in commodity prices and fluctuations in foreign currency exchange rates) which may affect the value of our investments as well as our ability to raise capital or refinance existing indebtedness and the cost of doing so;
- exposure to interest rate risk, including interest rate volatility, may negatively impact our results of operations, financial position or cash flow;
- future investment results, including the impact of realized losses (including other-than-temporary impairment charges) may diminish the value of our invested assets and negatively impact our profitability, our financial condition and our liquidity;
- the ultimate outcome of lawsuits filed against us and other legal and regulatory proceedings to which we are subject;
- our ability to make anticipated changes to certain non-guaranteed elements of our life insurance products;
- our ability to obtain adequate and timely rate increases on our health products, including our long-term care business;
- the receipt of any required regulatory approvals for dividend and surplus debenture interest payments from our insurance subsidiaries;
- mortality, morbidity, the increased cost and usage of health care services, persistency, the adequacy of our previous reserve estimates, changes in the health care market and other factors which may affect the profitability of our insurance products;
- the recoverability of our deferred tax assets and the effect of potential ownership changes and tax rate changes on their value;
- our assumption that the positions we take on our tax return filings will not be successfully challenged by the IRS;
- changes in accounting principles and the interpretation thereof;
- our ability to continue to satisfy the financial ratio and balance requirements and other covenants of our debt agreements;
- our ability to identify products and markets in which we can compete effectively against competitors with greater market share, higher ratings, greater financial resources and stronger brand recognition;
- our ability to generate sufficient liquidity to meet our debt service obligations and other cash needs;
- changes in capital deployment opportunities;
- our ability to maintain effective controls over financial reporting and modeling;
- our ability to continue to recruit and retain productive agents and distribution partners;
- customer response to new products, distribution channels and marketing initiatives;
- inflation or other unfavorable economic or business conditions may impact the sales and persistency of insurance products, a portion of our insurance policy benefits affected by increased medical coverage costs and various selling, general and administrative expenses;
- our ability to maintain the financial strength ratings of CNO and our insurance company subsidiaries as well as the impact of our ratings on our business, our ability to access capital, and the cost of capital;
- regulatory changes or actions, now or in the future, including: those relating to regulation of the financial affairs of our insurance companies, such as the calculation of risk-based capital and minimum capital requirements, and payment of dividends and surplus debenture interest to us; regulation of the sale, underwriting and pricing of products; health care regulation affecting health insurance products; and privacy laws and regulations;
- changes in the Federal income tax laws and regulations which may affect or eliminate the relative tax advantages of some of our products or affect the value of our deferred tax assets;
- availability and effectiveness of reinsurance arrangements, as well as the impact of any defaults or failure of reinsurers to perform;
- the use or anticipated use of artificial intelligence ("AI") technologies, including generative AI, by us or third-parties;
- the performance of third-party service providers (both domestic and international) and potential difficulties arising from outsourcing arrangements;
- expectations for the growth rate of sales, collected premiums, annuity deposits and assets;
- interruption in telecommunication, information technology or other operational systems or failure to maintain the security, confidentiality or privacy of sensitive data on such systems;
- events of terrorism, natural disasters or other catastrophic events, including potential adverse impacts from climate change which may increase the frequency or severity of weather-related disasters;
- cyber-security attacks, risk of data loss and other security breaches;
- ineffectiveness of risk management policies and procedures in identifying, monitoring and managing risks; and
- the risk factors or uncertainties listed from time to time in our filings with the SEC.

Other factors and assumptions not identified above are also relevant to the forward-looking statements, and if they prove incorrect, could also cause actual results to differ materially from those projected.

All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by the foregoing cautionary statement. Our forward-looking statements speak only as of the date made. We assume no obligation to update or to publicly announce the results of any revisions to any of the forward-looking statements to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the forward-looking statements.

The reporting of risk-based capital ("RBC") measures is not intended for the purpose of ranking any insurance company or for use in connection with any marketing, advertising or promotional activities.

### OVERVIEW

We are a holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. We focus on serving middle-income pre-retiree and retired Americans, which we believe are attractive, underserved, high growth markets. We sell our products through exclusive agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing.

We view our operations as three insurance product lines (annuity, health and life) and the investment and fee income segments. Our segments are aligned based on their common characteristics, comparability of profit margins and the way the chief operating decision maker makes operating decisions and assesses the performance of the business.

Our insurance product line segments (annuity, health and life) include marketing, underwriting and administration of the policies our insurance subsidiaries sell. The business written in each of the three product categories through all of our insurance subsidiaries is aggregated allowing management and investors to assess the performance of each product category. When analyzing profitability of these segments, we use insurance product margin as the measure of profitability, which is: (i) insurance policy income; and (ii) net investment income allocated to the insurance product lines; less (i) insurance policy benefits; (ii) interest credited to policyholders; (iii) amortization of deferred acquisition costs and present value of future profits, non-deferred commissions; and (iv) advertising expense. Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average insurance liabilities, net of insurance intangibles, for the block in each period. Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account values for interest sensitive products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.

Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes insurance product margin and income from insurance products help provide an additional understanding of the business and a more meaningful analysis of the results of our insurance product lines.

We market our products through the Consumer and Worksite Divisions that reflect the customers served by the Company. The Consumer and Worksite Divisions are primarily focused on marketing insurance products, several types of which are sold in both divisions and underwritten in the same manner.

The Consumer Division serves individual consumers, engaging with them on the phone, virtually, online, face-to-face with agents, or through a combination of sales channels. This structure unifies consumer capabilities into a single division and integrates the strength of our agent sales forces with one of the largest direct-to-consumer insurance businesses with proven experience in advertising, web/digital and call center support.

The Worksite Division focuses on the sale of voluntary benefit life and health insurance products in the workplace for businesses, associations, and other membership groups, interacting with customers at their place of employment and virtually. The Worksite Division also offers employer benefits services that seek to increase benefits engagement and reduce costs for employers and their employees. These services include: benefit administration technology, year-round advocacy, enrollment, benefits compliance and communications services.

The investment segment involves the management of our capital resources, including investments and the management of corporate debt and liquidity. Our measure of profitability of this segment is the total net investment income not allocated to the insurance products. Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our FHLB investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from COLI and alternative investment income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.

Our fee income segment includes the earnings generated from sales of third-party insurance products (primarily Medicare Advantage), services provided by Optavise, LLC ("Optavise") and the operations of our broker-dealer and registered investment advisor. The resulting fee income metric is the fee income segment's measure of profitability.

Expenses not allocated to product lines primarily include the expenses of our corporate operations, excluding interest expense on debt.

A wide variety of factors continue to impact financial and economic conditions. Consumer and economic uncertainty due to rapid changes in global trade policies, including the imposition of tariffs and potential changes to existing tariffs, are also causing market volatility and heightening concerns regarding inflation. Reactions to these factors and fluctuations in the value of the U.S. dollar compared to foreign currencies may result in reduced economic growth in the United States, the targeted nations and globally, increase inflation, disrupt global supply chains and increase volatility in financial markets, including currency and interest rate markets.

The following summarizes our earnings for the six months ended June 30, 2025 and 2024 (dollars in millions, except per share data):

| Insurance product margin | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Annuity margin | $54.8 | $76.1 | $109.3 | $128.1 |
| Health margin | 134.0 | 135.9 | 260.2 | 258.9 |
| Life margin | 63.6 | 63.1 | 131.8 | 117.7 |
| Total insurance product margin | 252.4 | 275.1 | 501.3 | 504.7 |
| Allocated expenses | (149.4) | (154.6) | (310.6) | (316.2) |
| Income from insurance products | 103.0 | 120.5 | 190.7 | 188.5 |
| Fee income | 0.8 | 0.8 | — | 12.1 |
| Investment income not allocated to product lines | 33.8 | 44.8 | 71.8 | 57.1 |
| Expenses not allocated to product lines | (25.3) | (17.5) | (45.6) | (34.3) |
| Operating earnings before taxes | 112.3 | 148.6 | 216.9 | 223.4 |
| Income tax expense on operating income | (24.8) | (34.0) | (48.3) | (51.3) |
| Net operating income (a) | 87.5 | 114.6 | 168.6 | 172.1 |
| Net realized investment losses from disposals, impairments and change in allowance for credit losses | (21.8) | (21.9) | (35.0) | (26.5) |
| Net change in market value of investments recognized in earnings | 3.4 | 4.7 | 9.8 | 17.1 |
| Fair value changes related to agent deferred compensation plan | — | 3.5 | — | 3.5 |
| Changes in fair value of embedded derivative liabilities and market risk benefits | 25.2 | 16.8 | (44.4) | 80.8 |
| Other | (1.1) | (1.1) | (1.5) | (1.5) |
| Net non-operating income (loss) before taxes | 5.7 | 2.0 | (71.1) | 73.4 |
| Income tax (expense) benefit on non-operating income (loss) | (1.4) | (0.3) | 15.8 | (16.9) |
| Net non-operating income (loss) | 4.3 | 1.7 | (55.3) | 56.5 |
| Net income | $91.8 | $116.3 | $113.3 | $228.6 |
| Per diluted share |  |  |  |  |
| Net operating income | $0.87 | $1.05 | $1.66 | $1.56 |
| Net non-operating income (loss) | 0.04 | 0.01 | (0.55) | 0.52 |
| Net income | $0.91 | $1.06 | $1.11 | $2.08 |

66

(a) Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and MRBs related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) gains or losses related to material reinsurance transactions, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation, net of taxes; and (ix) other non-operating items including earnings attributable to variable interest entities, net of taxes ("net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry. The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

In addition, management uses these non-GAAP financial measures in its budgeting process, financial analysis of segment performance and in assessing the allocation of resources. We believe these non-GAAP financial measures enhance an investor's understanding of our financial performance and allow them to make more informed judgments about the Company as a whole. These measures also highlight operating trends that might not otherwise be apparent. However, net operating income is not a measurement of financial performance under GAAP and should not be considered as an alternative to cash flow from operating activities, as measures of liquidity, or as an alternative to net income as measures of our operating performance or any other measures of performance derived in accordance with GAAP. In addition, net operating income should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Net operating income has limitations as an analytical tool, and you should not consider such measure either in isolation or as a substitute for analyzing our results as reported under GAAP. Our definition and calculation of net operating income are not necessarily comparable to other similarly titled measures used by other companies due to different methods of calculation.

### GOVERNMENTAL REGULATION

Refer to "Governmental Regulation" in our 2024 Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 for information on our insurance and other governmental regulatory matters.

### CRITICAL ACCOUNTING ESTIMATES

Refer to "Critical Accounting Estimates" in our 2024 Annual Report on Form 10-K for information on our other accounting policies that we consider critical in preparing our consolidated financial statements.

### RESULTS OF OPERATIONS

The following tables and narratives summarize the operating results of our segments (dollars in millions):

| Insurance product margin Annuity: | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Insurance policy income | $8.4 | $9.3 | $18.2 | $16.6 |
| Net investment income | 155.3 | 140.5 | 303.3 | 275.0 |
| Insurance policy benefits | (10.0) | 8.4 | (20.3) | (2.9) |
| Interest credited | (73.4) | (61.2) | (141.7) | (119.5) |
| Amortization and non-deferred commissions (a) | (25.5) | (20.9) | (50.2) | (41.1) |
| Annuity margin | 54.8 | 76.1 | 109.3 | 128.1 |
| Health: |  |  |  |  |
| Insurance policy income | 412.5 | 403.6 | 824.5 | 802.0 |
| Net investment income | 75.9 | 75.1 | 151.0 | 149.4 |
| Insurance policy benefits | (313.3) | (302.3) | (633.6) | (610.8) |
| Amortization and non-deferred commissions (a) | (41.1) | (40.5) | (81.7) | (81.7) |
| Health margin | 134.0 | 135.9 | 260.2 | 258.9 |
| Life: |  |  |  |  |
| Insurance policy income | 230.4 | 228.6 | 459.3 | 451.3 |
| Net investment income | 37.8 | 36.7 | 75.4 | 73.2 |
| Insurance policy benefits | (144.5) | (144.6) | (282.6) | (288.6) |
| Interest credited | (13.8) | (12.4) | (26.8) | (24.9) |
| Amortization and non-deferred commissions (a) | (27.6) | (24.3) | (53.6) | (47.8) |
| Advertising expense | (18.7) | (20.9) | (39.9) | (45.5) |
| Life margin | 63.6 | 63.1 | 131.8 | 117.7 |
| Total insurance product margin | 252.4 | 275.1 | 501.3 | 504.7 |
| Allocated expenses: |  |  |  |  |
| Branch office expenses | (15.9) | (16.2) | (36.6) | (36.0) |
| Other allocated expenses | (133.5) | (138.4) | (274.0) | (280.2) |
| Income from insurance products | 103.0 | 120.5 | 190.7 | 188.5 |
| Fee income | 0.8 | 0.8 | — | 12.1 |
| Investment income not allocated to product lines | 33.8 | 44.8 | 71.8 | 57.1 |
| Expenses not allocated to product lines | (25.3) | (17.5) | (45.6) | (34.3) |
| Operating earnings before taxes | 112.3 | 148.6 | 216.9 | 223.4 |
| Income tax expense on operating income | (24.8) | (34.0) | (48.3) | (51.3) |
| Net operating income | $87.5 | $114.6 | $168.6 | $172.1 |

(a) Amortization and non-deferred commissions are comprised of: (i) the amortization of deferred acquisition costs and present value of future profits; and (ii) commission expenses that are not directly related to the successful acquisition of new or renewal insurance contracts and, therefore, are not eligible to be deferred. Such non-deferred commissions are included in other operating costs and expenses on the consolidated statement of operations.

***General:*** CNO is the top tier holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. We view our operations by segments, which consist of insurance product lines. These products are distributed by our two divisions. The Consumer Division serves individual consumers, engaging with them on the phone, virtually, online, face-to-face with agents, or through a combination of sales channels. The Worksite Division focuses on the sale of voluntary benefit life and health insurance products in the workplace for businesses, associations, and other membership groups, interacting with customers at their place of employment and virtually.

Insurance product margin is management's measure of the profitability of its annuity, health and life product lines' performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs. Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes insurance product margin and income from insurance products help provide an additional understanding of the business and a more meaningful analysis of the results of our insurance product lines.

Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average insurance liabilities for the block in each period. Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account values for interest sensitive products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities. Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our FHLB investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from COLI and alternative investment income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.

***Summary of Operating Results:*** Net operating income was $87.5 million in the second quarter of 2025, compared to $114.6 million in the second quarter of 2024, and was $168.6 million in the first six months of 2025, compared to $172.1 million in the first six months of 2024.

Operating return on equity ("Operating ROE") (a non-GAAP measure) is equal to the trailing four quarters of net operating income divided by average shareholders' equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards. As of June 30, 2025, our 2025 operating ROE is on target with our guidance of an approximate 50 basis point improvement from our 2024 run rate ratio of 10 percent.

Insurance product margin was $252.4 million in the second quarter of 2025, compared to $275.1 million in the second quarter of 2024, and was $501.3 million in the first six months of 2025, compared to $504.7 million in the first six months of 2024. Excluding a significant item related to traditional life in the first quarter of 2025, the insurance product margin was $494.5 million for the first six months of 2025. Fluctuations by product line are discussed in greater detail in the narratives that follow.

Total net investment income (comprised of investment income allocated and not allocated to products) increased 2 percent to $302.8 million in the second quarter of 2025, as compared to $297.1 million in the second quarter of 2024, and 8 percent to $601.5 million in the first six months of 2025, compared to $554.7 million in the first six months of 2024. Investment income allocated to products increased $16.7 million in the second quarter of 2025 as compared to second quarter of 2024, and

$32.1 million in the first six months of 2025 when compared to prior year as a result of growth in the business and higher yields. The higher yields reflect continued new money rates in excess of 6 percent over the past 10 quarters. Investment income not allocated decreased $11.0 million during the second quarter of 2025 as compared to the second quarter of 2024 and increased $14.7 million during the first six months of 2025 when compared to the prior year, including losses on alternative investments of $24.3 million during the first quarter of 2024.

Total allocated and unallocated expenses are summarized in the table below (dollars in millions):

|  | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Expenses allocated to product lines | $149.4 | $154.6 | $310.6 | $316.2 |
| Expenses not allocated to product lines | 25.3 | 17.5 | 45.6 | 34.3 |
| Adjusted total | $174.7 | $172.1 | $356.2 | $350.5 |

Total allocated and unallocated expenses in the first six months of 2025 were up slightly as compared to the same period in the prior year, and were in line with our expectations. Our expense ratio was 19.4 percent and 19.8 percent for the six months ended June 30, 2025 and 2024, respectively. Expenses are seasonally higher in the first quarter of the year. The expense ratio is defined as total allocated and unallocated expenses divided by the sum of insurance policy income and net investment income allocated to products.

The fee income segment is summarized below (dollars in millions):

|  | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Fee revenue | $33.5 | $32.0 | $80.9 | $82.5 |
| Operating costs and expenses | (32.7) | (31.2) | (80.9) | (70.4) |
| Net fee income | $0.8 | $0.8 | $— | $12.1 |

Net fee income remained the same in the second quarter of 2025 as compared to the second quarter of 2024 but decreased in the first six months of 2025 as compared to the first six months of 2024, primarily due to the timing of income recognition on sales of third-party products by our Consumer Division in the first quarter of 2025. In the past year, we have expanded the number of carriers and the volume of sales from newer carriers. In addition, while the percentage of policies exchanged for new policies effective in 2025 did not materially change from the prior year, exchanges from our long-tenured carriers to our newer carriers increased as a percentage of total exchanges. Most exchanges occur in the fourth and first quarters. We hold a constraint on the income from new carriers until we build some persistency experience. Net fee income decreased as a result of this constraint in addition to higher agent retention in the first quarter of 2025, as compared to the first quarter of 2024.

Investment income not allocated to product lines generally fluctuates from period to period based on the performance of our alternative investments (which are typically reported one quarter in arrears); the earnings related to the investments underlying our COLI; the spread we earn from our FHLB investment borrowing and FABN programs; the level of prepayment income (including call premiums) and trading account income; and the impact of annual option forfeitures related to fixed indexed annuity surrenders. The decrease in investment income not allocated to products in the second quarter of 2025, as compared to the second quarter of 2024, was primarily due to lower option forfeitures as a result of lower surrenders and lower in the money options, tighter spreads in the FHLB program and higher interest expense on higher average debt outstanding. The increase in investment income not allocated to products in the first six months of 2025, as compared to the first six months of 2024, was primarily due to a loss on alternative investments in the first quarter of 2024.

The effective tax rate for the first six months of 2025 was 22.3 percent.

### Margin from Annuity Products (dollars in millions):

| Annuity margin: Fixed indexed annuities | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Insurance policy income | $6.7 | $7.2 | $13.9 | $13.2 |
| Net investment income | 127.8 | 113.8 | 248.7 | 222.2 |
| Insurance policy benefits | (5.0) | (2.6) | (10.5) | (8.4) |
| Interest credited | (60.8) | (49.4) | (116.5) | (96.1) |
| Amortization and non-deferred commissions | (23.3) | (19.1) | (45.7) | (37.6) |
| Margin from fixed indexed annuities | $45.4 | $49.9 | $89.9 | $93.3 |
| Average net insurance liabilities | $10,543.4 | $9,758.1 | $10,314.6 | $9,697.2 |
| Margin/average net insurance liabilities | 1.72% | 2.05% | 1.74% | 1.92% |
| Fixed interest annuities |  |  |  |  |
| Insurance policy income | $0.2 | $0.4 | $0.7 | $0.5 |
| Net investment income | 21.8 | 21.1 | 43.4 | 41.7 |
| Insurance policy benefits | (0.1) | 0.1 | 0.1 | (0.3) |
| Interest credited | (11.8) | (11.3) | (23.9) | (22.4) |
| Amortization and non-deferred commissions | (2.1) | (1.6) | (4.2) | (3.2) |
| Margin from fixed interest annuities | $8.0 | $8.7 | $16.1 | $16.3 |
| Average net insurance liabilities | $1,591.7 | $1,569.4 | $1,595.6 | $1,578.7 |
| Margin/average net insurance liabilities | 2.01% | 2.22% | 2.02% | 2.06% |
| Other annuities |  |  |  |  |
| Insurance policy income | $1.6 | $1.7 | $3.7 | $2.9 |
| Net investment income | 5.6 | 5.6 | 11.1 | 11.1 |
| Insurance policy benefits | (5.0) | 10.9 | (10.0) | 5.8 |
| Interest credited | (0.7) | (0.5) | (1.2) | (1.0) |
| Amortization and non-deferred commissions | (0.1) | (0.2) | (0.3) | (0.3) |
| Margin from other annuities | $1.4 | $17.5 | $3.3 | $18.5 |
| Average net insurance liabilities | $398.5 | $426.4 | $400.4 | $433.2 |
| Margin/average net insurance liabilities | 1.41% | 16.42% | 1.65% | 8.54% |
| Total annuity margin | $54.8 | $76.1 | $109.3 | $128.1 |
| Average net insurance liabilities | $12,533.6 | $11,753.9 | $12,310.6 | $11,709.1 |
| Margin/average net insurance liabilities | 1.75% | 2.59% | 1.78% | 2.19% |

71

***Margin from fixed indexed annuities*** was $45.4 million in the second quarter of 2025, compared to $49.9 million in the second quarter of 2024, and was $89.9 million in the first six months of 2025 compared to $93.3 million in the first six months of 2024. The margins have decreased in both the second quarter and the first six months of 2025, as compared to the same periods in 2024, primarily due to favorable movement in the MRB in the second quarter of 2024, partially offset by growth in the block. Spread income has increased due to growth in the block while the increases in yield have been partially offset by increases in credited rates. Average net insurance liabilities (policyholder account balances less: (i) amounts related to reinsured business; (ii) deferred acquisition costs; (iii) present value of future profits; and (iv) the value of unexpired options credited to insurance liabilities) were $10,543.4 million and $9,758.1 million in the second quarters of 2025 and 2024, respectively, and $10,314.6 million and $9,697.2 million in the first six months of 2025 and 2025, respectively, driven by deposits and reinvested returns in excess of withdrawals. The increase in net insurance liabilities results in higher net investment income allocated. The earned yield was 4.85 percent in the second quarter of 2025 up from 4.66 percent in the second quarter of 2024, and was 4.82 percent in the first six months of 2025 up from 4.58 percent in the first six months of 2025, reflecting higher portfolio yields.

Net investment income and interest credited exclude the change in market values of the underlying options supporting the fixed indexed annuity products and corresponding offsetting amount credited to policyholder account balances. Such amounts were $70.4 million and $34.9 million in the second quarters of 2025 and 2024, respectively, and were $6.9 million and $163.5 million in the first six months of 2025 and 2024, respectively.

***Margin from fixed interest annuities*** was $8.0 million in the second quarter of 2025, compared to $8.7 million in the second quarter of 2024, and was $16.1 million in the first six months of 2025 compared to $16.3 million in the first six months of 2024. Average net insurance liabilities were $1,591.7 million in the second quarter of 2025, compared to $1,569.4 million in the second quarter of 2024, and were $1,595.6 million in the first six months of 2025 compared to $1,578.7 million in the first six months of 2024, driven by deposits and reinvested returns in excess of withdrawals. The margins have decreased slightly in both the second quarter and the first six months of 2025, as compared to the same periods in 2024, primarily due to higher amortization. The increase in investment income resulting from the slight increase in the average net insurance liabilities and the increase in the earned yield was offset by an increase in credited interest. The earned yield was 5.48 percent in the second quarter of 2025, up from 5.38 percent in the second quarter of 2024, and was 5.44 percent in the first six months of 2025, up from 5.28 percent in the first six months of 2024, reflecting higher portfolio yields.

***Margin from other annuities*** was $1.4 million in the second quarter of 2025, compared to $17.5 million in the second quarter of 2024, and was $3.3 million in the first six months of 2025 compared to $18.5 million in the first six months of 2024. The margin on this relatively small block of business is sensitive to annuitant mortality related to contracts with life contingencies. An increase in mortality in this block will result in a decrease in insurance liabilities and insurance policy benefits. In the second quarter of 2024, we experienced annuitant mortality on five large policies in a closed block of payout annuities which reduced insurance policy benefits by $15.1 million.

### Margin from Health Products (dollars in millions):

| Health margin: Supplemental health | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Insurance policy income | $185.0 | $180.1 | $370.1 | $359.8 |
| Net investment income | 40.5 | 39.4 | 80.3 | 78.4 |
| Insurance policy benefits | (128.7) | (127.4) | (260.3) | (253.2) |
| Amortization and non-deferred commissions | (28.2) | (27.0) | (55.9) | (54.5) |
| Margin from supplemental health | $68.6 | $65.1 | $134.2 | $130.5 |
| Margin/insurance policy income | 37% | 36% | 36% | 36% |
| Medicare supplement |  |  |  |  |
| Insurance policy income | $155.9 | $155.8 | $312.2 | $307.5 |
| Net investment income | 1.2 | 1.3 | 2.4 | 2.7 |
| Insurance policy benefits | (119.5) | (111.5) | (239.5) | (227.9) |
| Amortization and non-deferred commissions | (9.4) | (10.1) | (18.8) | (20.3) |
| Margin from Medicare supplement | $28.2 | $35.5 | $56.3 | $62.0 |
| Margin/insurance policy income | 18% | 23% | 18% | 20% |
| Long-term care |  |  |  |  |
| Insurance policy income | $71.6 | $67.7 | $142.2 | $134.7 |
| Net investment income | 34.2 | 34.4 | 68.3 | 68.3 |
| Insurance policy benefits | (65.1) | (63.4) | (133.8) | (129.7) |
| Amortization and non-deferred commissions | (3.5) | (3.4) | (7.0) | (6.9) |
| Margin from long-term care | $37.2 | $35.3 | $69.7 | $66.4 |
| Margin/insurance policy income | 52% | 52% | 49% | 49% |
| Total health margin | $134.0 | $135.9 | $260.2 | $258.9 |
| Margin/insurance policy income | 32% | 34% | 32% | 32% |

***Margin from supplemental health*** business was $68.6 million in the second quarter of 2025 compared to $65.1 million in the second quarter of 2024, and was $134.2 million in the first six months of 2025 compared to $130.5 million in the first six months of 2024, reflecting growth in the business. The margin as a percentage of insurance policy income was 37 percent in the second quarter of 2025 compared to 36 percent in the prior year period, and was 36 percent in the first six months of 2025 and 2024.

Our supplemental health products (including specified disease, accident and hospital indemnity products) generally provide fixed or limited benefits. For example, payments under cancer insurance policies are generally made directly to, or at the direction of, the policyholder following diagnosis of, or treatment for, a covered type of cancer. Approximately two-thirds of our supplemental health policies inforce (based on policy count) are sold with return of premium or cash value riders. The return of premium rider generally provides that after a policy has been inforce for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy. The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned. Accordingly, the net cash flows from these products generally result in the accumulation of amounts in the early years of a policy (reflected in our earnings as reserve increases which is a component of insurance policy benefits) which will be paid out as benefits in later policy years (reflected in our earnings as reserve decreases which offset the recording of benefit payments). As the policies age, insurance policy benefits will typically increase, but the increase in benefits will be partially offset by investment income earned on the accumulated assets.

***Margin from Medicare supplement*** business was $28.2 million and $35.5 million in the second quarters of 2025 and 2024, respectively, and $56.3 million and $62.0 million in the first six months of 2025 and 2024, respectively. The decrease in the Medicare supplement margin in the 2025 periods, as compared to the 2024 periods is primarily due to modestly unfavorable claims in the second quarter of 2025 compared to favorable claim experience in the second quarter of 2024. Insurance policy income was $155.9 million in the second quarter of 2025, compared to $155.8 million in the second quarter of 2024, and was $312.2 million in the first six months of 2025, compared to $307.5 million in the first six months of 2024. We continue to invest in both our Medicare supplement products and Medicare Advantage distribution to meet our customers' needs and preferences. We receive fee income when Medicare Advantage policies of other carriers are sold, which is recorded in our Fee income segment.

Medicare supplement business consists of both individual and group policies. Government regulations generally require we attain and maintain a ratio of total benefits incurred to total premiums earned (excluding changes in policy benefits reserves which is a component of Insurance policy benefits) of not less than 65 percent on individual products and not less than 75 percent on group products. The ratio is determined after three years from the original issuance of the policy and over the lifetime of the policy and measured in accordance with statutory accounting principles. Since the insurance product liabilities we establish for Medicare supplement business are subject to significant estimates, the ultimate claim liability we incur for a particular period is likely to be different than our initial estimate. Changes to our estimates are reflected in insurance policy benefits in the period the change is determined.

***Margin from Long-term care products*** was $37.2 million and $35.3 million in the second quarters of 2025 and 2024, respectively, and $69.7 million and $66.4 million in the first six months of 2025 and 2024, respectively. The increase in margin in the 2025 periods is primarily due to growth in the business from sales of our short duration Long-Term Care Fundamental product. The average benefit period for policies sold in 2025 is 13 months and 99 percent are policies with two years or less in benefits. In addition, effective October 1, 2024, we retain 100 percent of our long-term care new business as we discontinued ceding 25 percent of long-term care new business under a reinsurance agreement (this did not impact the inforce business that we previously ceded). As a result, margins are increasing modestly in 2025 and we expect to grow more in future years as earnings emerge from the sales.

### Margin from Life Products (dollars in millions):

| Life margin: Interest-sensitive life | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Insurance policy income | $48.0 | $46.9 | $96.1 | $93.5 |
| Net investment income | 13.9 | 13.2 | 27.8 | 26.4 |
| Insurance policy benefits | (20.7) | (18.6) | (40.6) | (38.5) |
| Interest credited | (13.7) | (12.3) | (26.6) | (24.6) |
| Amortization and non-deferred commissions | (5.6) | (5.3) | (10.7) | (10.4) |
| Margin from interest-sensitive life | $21.9 | $23.9 | $46.0 | $46.4 |
| Average net insurance liabilities | $1,106.9 | $1,063.0 | $1,101.5 | $1,059.6 |
| Interest margin | $0.2 | $0.9 | $1.2 | $1.8 |
| Interest margin/average net insurance liabilities | 0.07% | 0.34% | 0.22% | 0.34% |
| Underwriting margin | $21.7 | $23.0 | $44.8 | $44.6 |
| Underwriting margin/insurance policy income | 45% | 49% | 47% | 48% |
| Traditional life |  |  |  |  |
| Insurance policy income | $182.4 | $181.7 | $363.2 | $357.8 |
| Net investment income | 23.9 | 23.5 | 47.6 | 46.8 |
| Insurance policy benefits | (123.8) | (126.0) | (242.0) | (250.1) |
| Interest credited | (0.1) | (0.1) | (0.2) | (0.3) |
| Amortization and non-deferred commissions | (22.0) | (19.0) | (42.9) | (37.4) |
| Advertising expense | (18.7) | (20.9) | (39.9) | (45.5) |
| Margin from traditional life | $41.7 | $39.2 | $85.8 | $71.3 |
| Margin/insurance policy income | 23% | 22% | 24% | 20% |
| Margin excluding advertising expense/insurance policy income | 33% | 33% | 35% | 33% |
| Total life margin | $63.6 | $63.1 | $131.8 | $117.7 |

***Margin from interest-sensitive life*** business was $21.9 million in the second quarter of 2025, compared to $23.9 million in the second quarter of 2024, and was $46.0 million in the first six months of 2025, down from $46.4 million in the first six months of 2024. The decrease in margin in the periods of 2025, as compared to the same periods in 2024, reflects higher insurance policy benefits.

The interest margin was $0.2 million and $0.9 million in the second quarter of 2025 and 2024, respectively, and was $1.2 million in the first six months of 2025, compared to $1.8 million in the first six months of 2024. The earned yield was 5.02 percent and 4.97 percent in the second quarters of 2025 and 2024, respectively, and 5.05 percent and 4.98 percent in the first six months of 2025 and 2024, respectively. Interest credited to policyholders may be changed annually but is subject to minimum guaranteed rates and, as a result, any reduction in our earned rate may not be fully reflected in the rate credited to policyholders.

Net investment income and interest credited exclude the change in market values of the underlying options supporting the fixed indexed life products and corresponding offsetting amount credited to policyholder account balances. Such amounts were $9.1 million and $4.0 million in the second quarter of 2025 and 2024, respectively, and were $2.4 million and $15.1 million in the first six months of 2025 and 2024, respectively.

***Margin from traditional life*** business was $41.7 million and $39.2 million in the second quarters of 2025 and 2024, respectively, and was $85.8 million and $71.3 million in the first six months of 2025 and 2024, respectively. The first quarter of 2025 included a model refinement related to traditional life reserves, which increased margins $6.8 million. Excluding this significant item, the margin was $79.0 million in the first six months of 2025. The increase in the adjusted margin in the 2025 periods, as compared to the same periods in 2024, primarily reflects lower advertising expense.

Advertising expense was $18.7 million in the second quarter of 2025, down from $20.9 million in the comparable period in 2024, and was $39.9 million in the first six months of 2025, down from $45.5 million in the comparable period in 2024. The demand and cost of television advertising can fluctuate from period to period. We are disciplined with our marketing expenditures and will increase or decrease our marketing spend depending on the current economics of the purchase or other factors.

### Collected Premiums From Annuity and Interest-Sensitive Life Products (dollars in millions):

|  | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Annuities | $520.5 | $439.1 | $962.5 | $832.4 |
| Interest-sensitive life | 63.6 | 61.3 | 126.5 | 121.8 |
| Total collected premiums from annuity and interest-sensitive life products | $584.1 | $500.4 | $1,089.0 | $954.2 |

Collected premiums from annuity and interest-sensitive products increased 16.7 percent in the second quarter of 2025 compared to the second quarter of 2024, and increased 14.1% in the first six months of 2025 compared to first six months of 2024 primarily due to higher premium collections from fixed indexed annuity products.

### Investment Income Not Allocated to Product Lines (dollars in millions):

|  | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Net investment income | $483.7 | $409.1 | $795.2 | $878.3 |
| Allocated to product lines: |  |  |  |  |
| Annuity | (155.3) | (140.5) | (303.3) | (275.0) |
| Health | (75.9) | (75.1) | (151.0) | (149.4) |
| Life | (37.8) | (36.7) | (75.4) | (73.2) |
| Equity returns credited to policyholder account balances | (79.5) | (38.9) | (9.3) | (178.6) |
| Amounts allocated to product lines and credited to policyholder account balances | (348.5) | (291.2) | (539.0) | (676.2) |
| Impact of annual option forfeitures related to fixed indexed annuity surrenders | 1.5 | 6.0 | 5.0 | 12.2 |
| Amount related to variable interest entities and other non-operating items | (7.0) | (9.6) | (14.2) | (22.2) |
| Interest expense on debt | (24.6) | (21.8) | (51.8) | (37.5) |
| Interest expense on financing arrangements | (1.0) | (1.2) | (2.0) | (2.4) |
| Interest expense on investment borrowings from FHLB | (27.7) | (31.4) | (53.7) | (62.8) |
| Expenses related to FABN program | (27.7) | (10.9) | (55.6) | (18.5) |
| Less amounts credited to deferred compensation plans (offsetting investment income) | (14.9) | (4.2) | (12.1) | (13.8) |
| Total adjustments | (101.4) | (73.1) | (184.4) | (145.0) |
| Investment income not allocated to product lines | $33.8 | $44.8 | $71.8 | $57.1 |

The above table reconciles net investment income to investment income not allocated to product lines. Such amounts generally fluctuate from period to period based on the performance of our alternative investments (which are typically reported one quarter in arrears); the earnings related to the investments underlying our COLI; the spread we earn from our FHLB investment borrowing and FABN programs; the level of prepayment income (including call premiums) and trading account income; and the impact of annual option forfeitures related to fixed indexed annuity surrenders. The decrease in investment income not allocated to products in the second quarter of 2025, as compared to the second quarter of 2024, was primarily due to lower option forfeitures as a result of lower surrenders and lower in the money options, tighter spreads in the FHLB program and higher interest expense on higher average debt outstanding. The increase in investment income not allocated to products in the first six months of 2025, as compared to the first six months of 2024, was primarily due to a loss on alternative investments in the first quarter of 2024.

### Net Non-Operating Income (Loss):

The following summarizes our net non-operating income (loss) for the three and six months ended June 30, 2025 and 2024 (dollars in millions):

|  | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Net realized investment losses from disposals, impairments and change in allowance for credit losses | $(21.8) | $(21.9) | $(35.0) | $(26.5) |
| Net change in market value of investments recognized in earnings | 3.4 | 4.7 | 9.8 | 17.1 |
| Fair value changes related to agent deferred compensation plan | — | 3.5 | — | 3.5 |
| Changes in fair value of embedded derivative liabilities and market risk benefits | 25.2 | 16.8 | (44.4) | 80.8 |
| Other | (1.1) | (1.1) | (1.5) | (1.5) |
| Net non-operating income (loss) before taxes | $5.7 | $2.0 | $(71.1) | $73.4 |

Net realized investment losses in the three and six months ended June 30, 2025 were $21.8 million and $35.0 million, including increases in the allowance for credit losses of $1.0 million and $10.5 million, respectively. Net realized investment losses in the three and six months ended June 30, 2024, were $21.9 million and $26.5 million, respectively, net of reductions in the allowance for credit losses of $4.1 million and $5.6 million, respectively.

The change in market value of investments recognized in earnings was an increase of $3.4 million and $4.7 million in the second quarters of 2025 and 2024, respectively, and $9.8 million and $17.1 million in the first six months of 2025 and 2024, respectively. The change in value will fluctuate from period to period based on market conditions.

During the first six months of 2024, we recognized an increase in earnings of $3.5 million for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability. We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change.

We recognized an increase (decrease) in pre-tax earnings of $(44.4) million and $80.8 million in the first six months of 2025 and 2024, respectively, resulting from changes in the fair value of embedded derivative liabilities and MRBs related to our fixed indexed annuities. Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and MRBs. Interest rates declined in the first six months of 2025 as compared to an increase in the first six months of 2024. In addition, certain amounts as of and for the three months ended December 31, 2024 and March 31, 2025 were revised to conform to the current period’s presentation for the correction of an error that is immaterial to the reported periods. The change in pre-tax earnings of $(44.4) for the first six months of 2025, includes a change of $10.1 million for the revision. In addition to non-operating income and net income, the revision impacted shareholders’ equity and the related metrics of book value per common share, and the debt-to-capital ratio for those periods. The revision did not impact our operating earnings. Refer to "Revision of Prior Period Amounts" in the note to the consolidated financial statements entitled "Business, Basis of Presentation, and Significant Accounting Policies" for additional information.

Other non-operating items in the first six months of 2025, included $3.2 million of expense related to TechMod, a three-year project to modernize certain elements of our technology. In addition, other non-operating items included a reduction in the allowance for credit losses on reinsurance of $2.0 million.

### 2025 OUTLOOK

We are reaffirming our previously disclosed guidance and we have lowered the upper bound of our expected expense ratio to be in the range of 19.0 percent to 19.2 percent (as compared to our previous guidance of between 19.0 percent to 19.4 percent), reflecting better operating leverage as we continue to grow the business. We continue to expect a quarterly trend similar to 2024, starting on the high end in the first quarter of the year and then grading down throughout the year.

We continue to expect operating earnings per diluted share to be in the range of $3.70 to $3.90, excluding any significant items in the year. We continue to expect improved results in net investment income not allocated to product lines as compared to 2024, which assumes higher returns on our alternative investments. We continue to expect a modest decrease in fee income with most of the earnings to be recognized in the fourth quarter of 2025, reflecting the seasonality of the business and volatility in revenue recognition for Medicare Advantage sales. We continue to expect the effective tax rate to be generally consistent with prior years at approximately 23 percent.

We continue to expect excess cash flow to the holding company to be in the range of $200 million to $250 million.

We expect to continue to manage to: (i) a consolidated RBC ratio of 375 percent for our U.S. based insurance subsidiaries; (ii) minimum holding company liquidity of $150 million; and (iii) a target debt to total capital, excluding accumulated other comprehensive income (loss), in the range of 25 percent to 28 percent.

We expect to improve run rate operating ROE by 150 basis points through 2027 from a run rate ROE of 10 percent in 2024, including approximately 50 basis point improvement in 2025.

In the second quarter of 2025, we began TechMod, a three-year project to modernize certain elements of our technology, enabling continued growth of the business over the long-term. The initiative is expected to cost approximately $170 million over three years, including approximately $45 million in 2025. The substantial majority of the costs will be expensed as incurred, but will be excluded from operating earnings, and included as a component of non-operating earnings. The expenses excluded from operating earnings will be discrete expenses, one-time in nature, related to the three year initiative, and largely paid to third parties as well as some asset write-offs. The remainder of the costs will either be expensed as incurred or capitalized and amortized through operating earnings. The outlook metrics previously described include the expected impact of this initiative.

### LIQUIDITY AND CAPITAL RESOURCES

Our capital structure as of June 30, 2025 and December 31, 2024 was as follows (dollars in millions):

| Total capital: | June 30, 2025 | December 31, 2024 |
| --- | ---: | ---: |
| Corporate notes payable | $1,334.7 | $1,833.5 |
| Shareholders’ equity: |  |  |
| Common stock | 1.0 | 1.0 |
| Additional paid-in capital | 1,441.4 | 1,632.5 |
| Accumulated other comprehensive loss | (1,252.7) | (1,371.4) |
| Retained earnings | 2,333.0 | 2,253.1 |
| Total shareholders’ equity | 2,522.7 | 2,515.2 |
| Total capital | $3,857.4 | $4,348.7 |

79

The following table summarizes certain financial ratios as of and for the six months ended June 30, 2025 and as of and for the year ended December 31, 2024:

|  | June 30, 2025 | December 31, 2024 |
| --- | ---: | ---: |
| Book value per common share | $25.92 | $24.75 |
| Book value per common share, excluding accumulated other comprehensive income (loss) (a) | 38.79 | 38.25 |
| Debt to total capital ratios: |  |  |
| Corporate debt to total capital | 34.6% | 42.2% |
| Corporate debt to total capital, excluding accumulated other comprehensive income (loss) (a) | 26.1% | 32.1% |

(a) This non-GAAP measure differs from the corresponding GAAP measure presented immediately above, because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. However, this measure does not replace the corresponding GAAP measure.

The reduction in the debt to total capital ratios from December 31, 2024 was primarily due to the repayment of the 2025 Notes during the second quarter of 2025.

### Liquidity for Insurance Operations

Our insurance companies generally receive adequate cash flows from premium collections and investment income to meet their obligations. Life insurance, long-term care and supplemental health insurance and annuity liabilities are generally long-term in nature. Life and annuity policyholders may, however, withdraw funds or surrender their policies, subject to any applicable penalty provisions; there are generally no withdrawal or surrender benefits for long-term care insurance. We actively manage the relationship between the duration of our invested assets and the estimated duration of benefit payments arising from contract liabilities.

Three of the Company's insurance subsidiaries (Bankers Life, Washington National and Colonial Penn) are members of the FHLB. As members of the FHLB, our insurance subsidiaries have the ability to borrow on a collateralized basis from the FHLB. We are required to hold certain minimum amounts of FHLB common stock as a condition of membership in the FHLB, and additional amounts based on the amount of the borrowings. At June 30, 2025, the carrying value of the FHLB common stock was $106.7 million. As of June 30, 2025, collateralized borrowings from the FHLB totaled $2.4 billion and the proceeds were used to purchase variable rate fixed maturity securities with similar durations. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet. The borrowings are collateralized by investments with an estimated fair value of $3.3 billion at June 30, 2025, which are maintained in custodial accounts for the benefit of the FHLB.

Bankers Life has a FABN program pursuant to which Bankers Life may issue funding agreements to a Delaware statutory trust organized in series (the "Trust") to generate spread-based earnings. Under current authorizations, the maximum aggregate principal amount of funding agreements permitted to be outstanding at any one time under the FABN program is $4 billion. In June, September and December of 2024, Bankers Life issued funding agreements each to a series of the Trust in a principal amount of $750 million, $400 million, and $450 million, respectively. During January 2025, a $400.0 million funding agreement was repaid at maturity. The aggregate principal amount of funding agreements outstanding at June 30, 2025 was $2.6 billion. The activity related to the funding agreements is reported in investment income not allocated to product lines.

State laws generally give state insurance regulatory agencies broad authority to protect policyholders in their jurisdictions. Regulators have used this authority in the past to restrict the ability of our insurance subsidiaries to pay any dividends or other amounts without prior approval. We cannot be assured that the regulators will not seek to assert greater supervision and control over our insurance subsidiaries' businesses and financial affairs.

Our estimated consolidated statutory RBC ratio of our U.S. based insurance subsidiaries was 378 percent at June 30, 2025, compared to 383 percent at December 31, 2024. In the first six months of 2025, the RBC ratio reflected: (i) our estimated consolidated statutory operating earnings of $35.5 million and (ii) insurance company dividends, net of capital contributions of $44.6 million that were paid to the holding company. Our RBC ratio at June 30, 2025, exceeded our targeted RBC ratio of 375 percent and the minimum 350 percent that is reflected in our risk appetite statement that we share and discuss with rating agencies and insurance regulators. We believe that the 375 percent RBC ratio target continues to adequately support our financial strength and credit ratings.

In 2023, we formed CNO Bermuda Re, Ltd. ("CNO Bermuda Re"), a Bermuda exempted company, which is an indirect wholly owned subsidiary of CNO. CNO Bermuda Re is registered by and subject to the supervision of the Bermuda Monetary Authority ("BMA") as a Class C insurer under the Bermuda Insurance Act 1978 and its related rules and regulations, each as amended. Pursuant to the Capital and Liquidity Maintenance Agreement ("CLMA") between CNO Bermuda Re and CDOC, CDOC will contribute funds to CNO Bermuda Re in the event: (i) CNO Bermuda Re's statutory economic capital and surplus is less than 150 percent of its enhanced capital requirement at the end of any calendar quarter; or (ii) CNO Bermuda Re's liquid assets are insufficient to meet its contractual obligations to ceding insurers, in each case, unless Bankers Life has provided notice of recapture pursuant to the terms of a modified coinsurance agreement between it and CNO Bermuda Re. Further, CNO Bermuda Re may not pay any dividends or make any capital distributions to its parent and/or affiliates within the five years following the 2023 reinsurance transaction unless approved by the BMA. CNO Bermuda Re is subject to regulation in Bermuda where the BMA has broad supervisory and administrative powers relating to granting and revoking licenses to transact reinsurance business, the approval of specific reinsurance transactions, capital requirements and solvency standards, limitations on dividends or distributions to shareholders, the nature of and limitations on investments, and the filing of financial statements in accordance with prescribed or permitted accounting practices. Future regulatory changes made by the BMA or other events may impact the capital efficiency of the reinsurance structure and could require the holding company to contribute additional capital to CNO Bermuda Re or Bankers Life to recapture the ceded business.

Our insurance subsidiaries transfer exposure to certain risk to others through reinsurance arrangements. When we obtain reinsurance, we are still liable for those transferred risks in the event the reinsurer defaults on its obligations. The failure, insolvency, inability or unwillingness of one or more of the Company's reinsurers to perform in accordance with the terms of its reinsurance agreement could negatively impact our earnings or financial position and our consolidated statutory RBC ratio.

### Financial Strength Ratings of our Insurance Subsidiaries

Financial strength ratings provided by Moody's Investor Services, Inc. ("Moody's"), S&P, AM Best Company ("AM Best") and Fitch Ratings ("Fitch") are the rating agency's opinions of the ability of our insurance subsidiaries to pay policyholder claims and obligations when due.

S&P most recently affirmed its "A-" financial strength ratings of our primary insurance subsidiaries on June 24, 2025. The outlook for these ratings remains stable. S&P financial strength ratings range from "AAA" to "D" and some companies are not rated. An insurer rated "A", in S&P's opinion, has strong financial security characteristics, but is somewhat more likely to be affected by adverse business conditions than are insurers with higher ratings. Pluses and minuses show the relative standing within a category. S&P has 22 possible ratings. There are six ratings above the "A-" rating of our primary insurance subsidiaries and 15 ratings that are below that rating.

Moody's most recently affirmed its "A3" financial strength ratings of our primary insurance subsidiaries on June 18, 2025. The outlook for these ratings remains stable. Moody’s financial strength ratings range from "Aaa" to "C". These ratings may be supplemented with numbers "1", "2", or "3" to show relative standing within a category. In Moody's view, an insurer rated "A" offers good financial security, however, certain elements may be present which suggests a susceptibility to impairment in the future. Moody's has 21 possible ratings. There are six ratings above the "A3" rating of our primary insurance subsidiaries and 14 ratings that are below that rating.

On February 26, 2025, AM Best affirmed its "A" financial strength ratings of our primary insurance subsidiaries and the outlook for these ratings remains stable. The "A" rating is assigned to companies that have an excellent ability, in AM Best's opinion, to meet their ongoing obligations to policyholders. AM Best ratings for the industry currently range from "A++ (Superior)" to "D (In Liquidation)" and some companies are not rated. AM Best has 13 possible ratings. There are two ratings above the "A" rating of our primary insurance subsidiaries and ten ratings that are below that rating.

On October 29, 2024, Fitch most recently affirmed its "A" financial strength ratings of our primary insurance subsidiaries and the outlook for these ratings remains stable. An insurer rated "A", in Fitch's opinion, indicates a low expectation of ceased or interrupted payments and indicates strong capacity to meet policyholder and contract obligations. This capacity may, nonetheless, be more vulnerable to changes in circumstances or in economic conditions than is the case for higher ratings. Fitch ratings for the industry range from "AAA Exceptionally Strong" to "D Distressed" and some companies are not rated. Pluses and minuses show the relative standing within a category. Fitch has 24 possible ratings. There are five ratings above the "A" rating of our primary insurance subsidiaries and 18 ratings that are below that rating.

Rating agencies have increased the frequency and scope of their credit reviews and requested additional information from the companies that they rate, including us. They may also adjust upward the capital and other requirements employed in their rating models for maintenance of certain ratings levels. We cannot predict what actions rating agencies may take, or what actions we may take in response. Accordingly, downgrades and outlook revisions related to us or the life insurance industry may occur in the future at any time and without notice by any rating agency. These could increase policy surrenders and withdrawals, adversely affect relationships with our distribution channels, reduce new sales, reduce our ability to borrow and increase our future borrowing costs.

### Liquidity of the Holding Companies

*Availability and Sources and Uses of Holding Company Liquidity; Limitations on Ability of Insurance Subsidiaries to Make Dividend and Surplus Debenture Interest Payments to the Holding Companies; Limitations on Holding Company Activitie*s

CNO and CDOC, Inc. ("CDOC", our wholly owned subsidiary and the immediate parent of Washington National and Conseco Life Insurance Company of Texas ("CLTX")) are holding companies with no business operations of their own; they depend on their operating subsidiaries for cash to make principal and interest payments on debt, and to pay administrative expenses and income taxes. CNO and CDOC receive cash from insurance subsidiaries, consisting of dividends and distributions, interest payments on surplus debentures and tax-sharing payments, as well as cash from non-insurance subsidiaries consisting of dividends, distributions, loans and advances. The principal non-insurance subsidiaries that provide cash to CNO and CDOC are 40\|86 Advisors, Inc., which receives fees from the insurance subsidiaries for investment services, and CNO Services, LLC which receives fees from the insurance subsidiaries for providing administrative services. The agreements between our insurance subsidiaries and CNO Services, LLC and 40\|86 Advisors, Inc., respectively, were previously approved by the domestic insurance regulator for each insurance company, and any payments thereunder do not require further regulatory approval. Refer to "Liquidity for Insurance Operations" above regarding the CLMA and limitations on

CNO Bermuda Re's ability to pay dividends or other capital distributions to CDOC.

At June 30, 2025, CNO, CDOC and our other non-insurance subsidiaries held $187.1 million of unrestricted cash and cash equivalents which was above our minimum target level of $150 million.

The ability of our U.S. based insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from GAAP. These regulations generally permit dividends to be paid from statutory earned surplus of the insurance company without regulatory approval for any 12-month period in amounts equal to the greater of (or in some states, the lesser of): (i) statutory net gain from operations or net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. However, as each of the immediate U.S. based insurance subsidiaries of CDOC has significant negative earned surplus, any dividend payments from the insurance subsidiaries require the prior approval of the director or commissioner of the applicable state insurance department. CNO Bermuda Re may not pay any dividends or make any capital distributions to its parent and/or affiliates within the five years following the 2023 reinsurance transaction unless approved by the BMA. In the first six months of 2025, our U.S. based insurance subsidiaries paid dividends to CDOC totaling $82.0 million. We expect to receive regulatory approval for future dividends from our subsidiaries, but there can be no assurance that such payments will be approved or that the financial condition of our insurance subsidiaries will not change, making future approvals less likely.

CDOC holds surplus debentures from CLTX with an aggregate principal amount of $749.6 million. Interest payments on those surplus debentures do not require additional approval provided the RBC ratio of CLTX exceeds 100 percent (but do require prior written notice to the Texas Department of Insurance). The estimated RBC ratio of CLTX was 324 percent at

June 30, 2025. CDOC also holds a surplus debenture from Colonial Penn with a principal balance of $160.0 million. Interest payments on that surplus debenture require prior approval by the Pennsylvania Insurance Department. Dividends and other payments from our non-insurance subsidiaries, including 40\|86 Advisors, Inc. and CNO Services, LLC, to CNO or CDOC do not require approval by any regulatory authority or other third party. However, insurance regulators may prohibit payments by our insurance subsidiaries to parent companies if they determine that such payments could be adverse to our policyholders or contractholders.

The insurance subsidiaries of CDOC receive funds to pay dividends primarily from: (i) the earnings of their direct businesses; (ii) tax sharing payments received from subsidiaries (if applicable); and (iii) with respect to CLTX, dividends received from subsidiaries. At June 30, 2025, the subsidiaries of CLTX had earned deficits as summarized below (dollars in millions):

| Subsidiaries of CLTX | Earned deficit | Additional information |
| --- | ---: | --- |
| Bankers Life | $— | (a) |
| Colonial Penn | (547.1) | (b) |
| Bankers Conseco Life Insurance Company | (2.5) | (c) |

(a) Bankers Life paid dividends of $65.0 million to CLTX in the first six months of 2025. Bankers Life may pay dividends without regulatory approval or prior notice for any 12-month period if such dividends are less than the greater of: (i) statutory net income for the prior year; or (ii) 10 percent of statutory capital and surplus as of the end of the preceding year. Dividends in excess of these levels require 30 days prior notice. Dividends in excess of earned surplus require prior approval from the Illinois Department of Insurance for return-of-capital distributions.

(b) The deficit is primarily due to transactions which occurred several years ago, including a tax planning transaction and the fee paid to recapture a block of business previously ceded to an unaffiliated insurer.

(c) The deficit is due to cumulative losses on our long-term care business.

A significant deterioration in the financial condition, earnings or cash flow of the material subsidiaries of CNO or CDOC for any reason could hinder such subsidiaries' ability to pay cash dividends or other disbursements to CNO and/or CDOC, which, in turn, could limit CNO's ability to meet debt service requirements and satisfy other financial obligations. In addition, we may choose to retain capital in our insurance subsidiaries or to contribute additional capital to our insurance subsidiaries to maintain or strengthen their surplus or fund reinsurance transactions, and these decisions could limit the amount available at our top tier insurance subsidiaries to pay dividends to the holding companies. In the first six months of 2025, CDOC made capital contributions of $37.4 million to CLTX.

At June 30, 2025, there were no amounts outstanding under our $250 million Revolving Credit Agreement and there are no scheduled repayments of our direct corporate obligations until May 2029.

Free cash flow is a measure of holding company liquidity and is calculated as: (i) dividends, management fees and surplus debenture interest payments received from our subsidiaries; plus (ii) earnings on corporate investments; less (iii) interest expense, corporate expenses and net tax payments. In the first six months of 2025, we generated approximately $48 million of such free cash flow. The Company expects to deploy its free cash flow into investments to accelerate profitable growth, common stock dividends and share repurchases. The amount and timing of future share repurchases (if any) will be based on business and market conditions and other factors including, but not limited to, available free cash flow, the current price of our common stock and investment opportunities. In the first six months of 2025, we repurchased 5.1 million shares of common stock for $199.9 million under our securities repurchase program, including $1.6 million of repurchases settled in the third quarter of 2025. The Company's Board of Directors authorized the repurchase of an additional $500.0 million of the Company's outstanding shares of common stock in February 2025. The Company had remaining repurchase authority of $540.4 million as of June 30, 2025.

In the first six months of 2025, dividends declared on common stock totaled $33.4 million ($0.33 per common share). In May 2025, the Company increased its quarterly common stock dividend to $0.17 per share from $0.16 per share.

S&P most recently affirmed its "BBB-" rating on our issuer credit and senior unsecured debt on June 24, 2025. The outlook for these ratings remains stable. In S&P's view, an obligation rated "BBB" exhibits adequate protection parameters. However, adverse economic conditions or changing circumstances are more likely to lead to a weakened capacity of the obligor to meet its financial commitment on the obligation. Pluses and minuses show the relative standing within a category. S&P has a total of 22 possible ratings ranging from "AAA (Extremely Strong)" to "D (Payment Default)". There are nine ratings above CNO's "BBB-" rating and 12 ratings that are below its rating.

Moody's most recently reviewed its "Baa3" rating on our senior unsecured debt on June 18, 2025. The outlook for these ratings remains stable. In Moody's view, obligations rated "Baa" are subject to moderate credit risk and may possess certain speculative characteristics. A rating is supplemented with numerical modifiers "1", "2" or "3" to show the relative standing within a category. Moody's has a total of 21 possible ratings ranging from "Aaa" to "C". There are nine ratings above CNO's "Baa3" rating and 11 ratings that are below its rating.

On February 26, 2025, AM Best affirmed its "bbb" rating on our issuer credit and senior unsecured debt and the outlook for these ratings is stable. In AM Best's view, a company rated "bbb" has an adequate ability to meet the terms of its obligations; however, the issuer is more susceptible to changes in economic or other conditions. Pluses and minuses show the relative standing within a category. AM Best has a total of 21 possible ratings ranging from "aaa (Exceptional)" to "c (In default)". There are eight ratings above CNO's "bbb" rating and 12 ratings that are below its rating.

On October 29, 2024, Fitch most recently affirmed its "BBB" rating on our senior unsecured debt ratings. The outlook for these ratings is stable. In Fitch's view, an obligation rated "BBB" indicates that expectations of default risk are currently low. The capacity for payment of financial commitments is considered adequate but adverse business or economic conditions are more likely to impair this capacity. Pluses and minuses show the relative standing within a category. Fitch has a total of 24 possible ratings ranging from "AAA" to "D". There are eight ratings above CNO's "BBB" rating and 15 ratings that are below its rating.

We believe that the existing cash available to the holding company, the cash flows to be generated from operations and other transactions will be sufficient to allow us to meet our debt service obligations, pay corporate expenses and satisfy other financial obligations. However, our cash flow is affected by a variety of factors, many of which are outside of our control, including insurance regulatory issues, competition, financial markets and other general business conditions. We cannot provide assurance that we will possess sufficient income and liquidity to meet all of our debt service requirements and other holding company obligations.

### INVESTMENTS

At June 30, 2025, the amortized cost, gross unrealized gains, gross unrealized losses, allowance for credit losses and estimated fair value of fixed maturities, available for sale, were as follows (dollars in millions):

| Investment grade (a): | Amortized cost | Gross unrealized gains | Gross unrealized losses | Allowance for credit losses | Estimated fair value |
| --- | ---: | ---: | ---: | ---: | ---: |
| Corporate securities | $13,380.8 | $105.1 | $(1,522.9) | $(24.4) | $11,938.6 |
| United States Treasury securities and obligations of United States government corporations and agencies | 217.9 | — | (29.7) | — | 188.2 |
| States and political subdivisions | 3,318.7 | 18.1 | (421.4) | (0.6) | 2,914.8 |
| Foreign governments | 113.6 | 0.5 | (13.8) | (0.8) | 99.5 |
| Asset-backed securities | 1,497.2 | 10.3 | (42.9) | (0.1) | 1,464.5 |
| Agency residential mortgage-backed securities | 910.7 | 9.7 | (1.3) | — | 919.1 |
| Non-agency residential mortgage-backed securities | 1,282.0 | 13.5 | (102.7) | — | 1,192.8 |
| Collateralized loan obligations | 1,091.7 | 3.8 | (5.0) | — | 1,090.5 |
| Commercial mortgage-backed securities | 2,158.9 | 5.2 | (120.7) | — | 2,043.4 |
| Total investment grade fixed maturities, available for sale | 23,971.5 | 166.2 | (2,260.4) | (25.9) | 21,851.4 |
| Below-investment grade (a) (b): |  |  |  |  |  |
| Corporate securities | 678.1 | 7.5 | (38.1) | (8.7) | 638.8 |
| States and political subdivisions | 23.6 | 0.1 | (2.2) | (2.3) | 19.2 |
| Asset-backed securities | 95.8 | — | (9.0) | — | 86.8 |
| Non-agency residential mortgage-backed securities | 326.0 | 23.3 | (5.9) | — | 343.4 |
| Commercial mortgage-backed securities | 133.8 | — | (24.2) | (2.2) | 107.4 |
| Total below-investment grade fixed maturities, available for sale | 1,257.3 | 30.9 | (79.4) | (13.2) | 1,195.6 |
| Total fixed maturities, available for sale | $25,228.8 | $197.1 | $(2,339.8) | $(39.1) | $23,047.0 |

(a) Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations ("NRSROs") (Moody's, S&P or Fitch), or if not rated by such firms, the rating assigned by the National Association of Insurance Commissioners (the "NAIC"). NAIC designations of "1" or "2" include fixed maturities generally rated investment grade (rated "Baa3" or higher by Moody's or rated "BBB-" or higher by S&P and Fitch). NAIC designations of "3" through "6" are referred to as below-investment grade (which generally are rated "Ba1" or lower by Moody's or rated "BB+" or lower by S&P and Fitch). References to investment grade or below-investment grade throughout our consolidated financial statements are determined as described above.

(b) Certain structured securities rated below-investment grade by NRSROs may be assigned a NAIC 1 or NAIC 2 designation based on the cost basis of the security relative to estimated recoverable amounts as determined by the NAIC. Refer to the table below for a summary of our fixed maturity securities, available for sale, by NAIC designations.

The NAIC evaluates the fixed maturity investments of insurers for regulatory and capital assessment purposes and assigns securities to one of six credit quality categories called NAIC designations, which are used by insurers when preparing their annual statements based on statutory accounting principles. The NAIC designations are generally similar to the credit quality designations of the NRSROs for marketable fixed maturity securities, except for certain structured securities. However, certain structured securities rated below investment grade by the NRSROs can be assigned NAIC 1 or NAIC 2 designations depending on the cost basis of the holding relative to estimated recoverable amounts as determined by the NAIC. The following summarizes the NAIC designations and NRSRO equivalent ratings:

|  |  |
| ---: | --- |
| NAIC Designation | NRSRO Equivalent Rating |
| 1 | AAA/AA/A |
| 2 | BBB |
| 3 | BB |
| 4 | B |
| 5 | CCC and lower |
| 6 | In or near default |

A summary of our fixed maturity securities, available for sale, by NAIC designations (or for fixed maturity securities held by non-regulated entities, based on NRSRO ratings) as of June 30, 2025 is as follows (dollars in millions):

| NAIC designation | Amortized cost | Estimated fair value | Percentage of total estimated fair value |
| ---: | ---: | ---: | ---: |
| 1 | $16,317.8 | $14,871.7 | 64.5% |
| 2 | 7,997.5 | 7,337.0 | 31.8 |
| Total NAIC 1 and 2 (investment grade) | 24,315.3 | 22,208.7 | 96.3 |
| 3 | 666.5 | 619.4 | 2.7 |
| 4 | 209.3 | 192.2 | 0.8 |
| 5 | 16.6 | 12.3 | 0.1 |
| 6 | 21.1 | 14.4 | 0.1 |
| Total NAIC 3, 4, 5 and 6 (below-investment grade) | 913.5 | 838.3 | 3.7 |
| Total | $25,228.8 | $23,047.0 | 100.0% |

86

#### Fixed Maturity Securities, Available for Sale

The following table summarizes the carrying values and gross unrealized losses of our fixed maturity securities, available for sale, by category as of June 30, 2025 (dollars in millions):

|  | Carrying value | Percent of fixed maturities | Gross unrealized losses | Percent of gross unrealized losses |
| --- | ---: | ---: | ---: | ---: |
| States and political subdivisions | $2,934.0 | 12.7% | $423.6 | 18.1% |
| Commercial mortgage-backed securities | 2,150.8 | 9.3 | 144.9 | 6.2 |
| Banks | 1,832.3 | 7.9 | 176.8 | 7.5 |
| Asset-backed securities | 1,551.3 | 6.7 | 51.9 | 2.2 |
| Non-agency residential mortgage-backed securities | 1,536.2 | 6.7 | 108.6 | 4.6 |
| Insurance | 1,213.1 | 5.3 | 174.6 | 7.4 |
| Utilities | 1,160.2 | 5.0 | 160.4 | 6.8 |
| Healthcare/pharmaceuticals | 1,091.0 | 4.7 | 217.9 | 9.3 |
| Collateralized loan obligations | 1,090.5 | 4.7 | 5.0 | 0.2 |
| Brokerage | 919.2 | 4.0 | 71.2 | 3.0 |
| Agency residential mortgage-backed securities | 919.1 | 4.0 | 1.3 | 0.1 |
| Technology | 791.8 | 3.4 | 147.2 | 6.3 |
| Food/beverage | 648.5 | 2.8 | 86.8 | 3.7 |
| Cable/media | 567.0 | 2.5 | 85.8 | 3.9 |
| Energy | 541.9 | 2.4 | 43.9 | 1.9 |
| Real estate/REITs | 406.4 | 1.8 | 37.2 | 1.6 |
| Transportation | 386.3 | 1.7 | 52.5 | 2.2 |
| Chemicals | 272.1 | 1.2 | 34.3 | 1.5 |
| Capital goods | 257.1 | 1.1 | 29.7 | 1.3 |
| Autos | 237.6 | 1.0 | 21.7 | 0.9 |
| Metals and mining | 203.5 | 0.9 | 11.9 | 0.5 |
| Education | 199.9 | 0.9 | 61.3 | 2.6 |
| Other | 2,137.2 | 9.3 | 191.3 | 8.2 |
| Total fixed maturities, available for sale | $23,047.0 | 100.0% | $2,339.8 | 100.0% |

#### Below-Investment Grade Securities

At June 30, 2025, the amortized cost of the Company's below-investment grade fixed maturity securities, available for sale, was $1,257.3 million, or 5.0 percent of the Company's fixed maturity portfolio (or $913.5 million, or 3.6 percent, of the Company's fixed maturity portfolio measured on credit quality ratings assigned by the NAIC). The estimated fair value of the below-investment grade portfolio was $1,195.6 million, or 95 percent of the amortized cost.

Below-investment grade corporate debt securities typically have different characteristics than investment grade corporate debt securities. Based on historical performance, probability of default by the borrower is significantly greater for below-investment grade corporate debt securities and in many cases severity of loss is relatively greater as such securities are generally unsecured and often subordinated to other indebtedness of the issuer. Also, issuers of below-investment grade corporate debt securities frequently have higher levels of debt relative to investment-grade issuers, hence, all other things being equal, are generally more sensitive to adverse economic conditions. The Company attempts to reduce the overall risk related to its investment in below-investment grade securities, as in all investments, through careful credit analysis, strict investment policy guidelines, and diversification by issuer and/or guarantor and by industry.

#### Structured Securities

At June 30, 2025, fixed maturity investments included structured securities with an estimated fair value of $7.2 billion, which represents 31.4 percent of all fixed maturity securities. The yield characteristics of structured securities generally differ in some respects from those of traditional corporate fixed-income securities or government securities. For example, interest and principal payments on structured securities may occur more frequently, often monthly. In many instances, we are subject to variability in the amount and timing of principal and interest payments. For example, in many cases, partial prepayments may occur at the option of the issuer and prepayment rates are influenced by a number of factors that cannot be predicted with certainty, including: the relative sensitivity of prepayments on the underlying assets backing the security to changes in interest rates and asset values; the availability of alternative financing; a variety of economic, geographic and other factors; the timing, pace and proceeds of liquidations of defaulted collateral; and various security-specific structural considerations (for example, the repayment priority of a given security in a securitization structure). In addition, the total amount of payments for non-agency structured securities may be affected by changes to cumulative default rates or loss severities of the related collateral.

The amortized cost and estimated fair value of structured securities at June 30, 2025, summarized by type of security, were as follows (dollars in millions):

| Type | Amortized cost | Estimated fair value Amount | Percent of fixed maturities |
| --- | ---: | ---: | ---: |
| Asset-backed securities | $1,593.0 | $1,551.3 | 6.7% |
| Agency residential mortgage-backed securities | 910.7 | 919.1 | 4.0 |
| Non-agency residential mortgage-backed securities | 1,608.0 | 1,536.2 | 6.7 |
| Collateralized loan obligations | 1,091.7 | 1,090.5 | 4.7 |
| Commercial mortgage-backed securities | 2,292.7 | 2,150.8 | 9.3 |
| Total structured securities | $7,496.1 | $7,247.9 | 31.4% |

Residential mortgage-backed securities ("RMBS") include transactions collateralized by agency-guaranteed and non-agency mortgage obligations. Non-agency RMBS investments are primarily categorized by underlying borrower credit quality: Prime, Alt-A, Non-Qualified Mortgage ("Non-QM"), and Subprime. Prime borrowers typically default with the lowest frequency, Alt-A and Non-QM default at higher rates, and Subprime borrowers default with the highest frequency. In addition to borrower credit categories, RMBS investments include Re-Performing Loan ("RPL") and Credit Risk Transfer ("CRT") transactions. RPL transactions include borrowers with prior difficulty meeting the original mortgage terms and were subsequently modified, resulting in a sustainable payback arrangement. CRT securities are collateralized by Government-Sponsored Enterprise ("GSE") conforming mortgages and Prime borrowers, but without an agency guarantee against default losses.

Commercial mortgage-backed securities ("CMBS") are secured by commercial real estate mortgages, generally income producing properties that are managed for profit. Property types include, but are not limited to, multi-family dwellings including apartments, retail centers, hotels, restaurants, hospitals, nursing homes, warehouses, and office buildings. While most CMBS have call protection features whereby underlying borrowers may not prepay their mortgages for stated periods of time without incurring prepayment penalties, recoveries on defaulted collateral may result in involuntary prepayments.

#### Net Realized and Unrealized Investment Losses

During the six months ended June 30, 2025, the $24.6 million of gross realized losses on sales of $525.1 million of fixed maturity securities, available for sale, primarily related to various corporate securities. Securities are generally sold at a loss following unforeseen sector or issuer-specific events or conditions, shifts in perceived credit quality relative values, or in connection with strategic asset repositionings related to changes in market conditions.

During the six months ended June 30, 2024, we recognized $33.5 million of realized losses on sales of $669.2 million of fixed maturity securities, available for sale, primarily related to various corporate securities and commercial mortgage-backed securities.

The following summarizes the investments sold at a loss during the first six months of 2025 which had been

continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period

indicated (dollars in millions):

|  | Number of issuers | At date of sale Amortized cost | Fair value |
| --- | ---: | ---: | ---: |
| Less than 6 months prior to sale | 3 | $24.4 | $18.3 |
| Greater than or equal to 6 months and less than 12 months prior to sale | 2 | 4.3 | 3.5 |
| Greater than 12 months prior to sale | 4 | 7.5 | 3.3 |
|  |  | $36.2 | $25.1 |

Future events may occur, or additional information may become available, which may necessitate future realized losses in our portfolio. Significant losses could have a material adverse effect on our consolidated financial statements in future periods.

The following table sets forth the amortized cost and estimated fair value of those fixed maturities, available for sale, with unrealized losses at June 30, 2025, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties. Structured securities frequently include provisions for periodic principal payments and permit periodic unscheduled payments.

*(Dollars in millions)*

|  | Amortized cost | Estimated fair value |
| --- | ---: | ---: |
| Due in one year or less | $143.5 | $142.1 |
| Due after one year through five years | 1,154.0 | 1,115.8 |
| Due after five years through ten years | 700.3 | 653.1 |
| Due after ten years | 11,047.2 | 9,069.0 |
| Subtotal | 13,045.0 | 10,980.0 |
| Structured securities | 4,162.0 | 3,848.1 |
| Total | $17,207.0 | $14,828.1 |

The following summarizes the investments in our portfolio rated below-investment grade not deemed to have credit losses which have been continuously in an unrealized loss position exceeding 20 percent of the cost basis as of June 30, 2025 (dollars in millions):

|  | Number of issuers | Cost basis | Unrealized loss | Estimated fair value |
| --- | ---: | ---: | ---: | ---: |
| Greater than or equal to 6 months and less than 12 months | 1 | $18.1 | $(4.0) | $14.1 |
| Greater than 12 months | 4 | 44.8 | (14.4) | 30.4 |
| Total |  | $62.9 | $(18.4) | $44.5 |

89

The following table summarizes the gross unrealized losses of our fixed maturity securities, available for sale, by category and ratings category as of June 30, 2025 (dollars in millions):

|  | Investment grade AAA/AA/A | BBB | Below-investment grade BB | B+ and below | Total gross unrealized losses |
| --- | ---: | ---: | ---: | ---: | ---: |
| States and political subdivisions | $414.7 | $6.7 | $0.3 | $1.9 | $423.6 |
| Healthcare/pharmaceuticals | 164.4 | 52.3 | 1.2 | — | 217.9 |
| Banks | 116.2 | 59.0 | 1.6 | — | 176.8 |
| Insurance | 99.5 | 72.6 | 2.5 | — | 174.6 |
| Utilities | 105.6 | 54.4 | 0.4 | — | 160.4 |
| Technology | 88.1 | 56.8 | 2.2 | 0.1 | 147.2 |
| Commercial mortgage-backed securities | 96.4 | 24.4 | 13.5 | 10.6 | 144.9 |
| Non-agency residential mortgage-backed securities | 91.5 | 11.1 | 0.3 | 5.7 | 108.6 |
| Cable/media | 6.9 | 64.6 | 13.6 | 0.7 | 85.8 |
| Food/beverage | 30.9 | 55.7 | 0.2 | — | 86.8 |
| Brokerage | 45.1 | 25.8 | 0.3 | — | 71.2 |
| Education | 55.7 | 5.6 | — | — | 61.3 |
| Transportation | 25.8 | 24.5 | — | 2.2 | 52.5 |
| Asset-backed securities | 19.8 | 23.1 | 7.8 | 1.2 | 51.9 |
| Energy | 11.5 | 32.4 | — | — | 43.9 |
| Real estate/REITs | 25.4 | 11.8 | — | — | 37.2 |
| Chemicals | 2.8 | 31.3 | 0.1 | 0.1 | 34.3 |
| United States Treasury securities and obligations of United States government corporations and agencies | 29.7 | — | — | — | 29.7 |
| Capital goods | 21.0 | 8.7 | — | — | 29.7 |
| Retail | 25.1 | 1.8 | 1.0 | 0.9 | 28.8 |
| Aerospace/defense | 7.6 | 15.2 | — | — | 22.8 |
| Autos | 4.8 | 16.8 | — | 0.1 | 21.7 |
| Consumer products | 10.9 | 1.7 | 8.3 | 0.5 | 21.4 |
| Building materials | 5.8 | 14.6 | — | 0.1 | 20.5 |
| Telecom | 0.3 | 13.5 | — | — | 13.8 |
| Foreign governments | 6.4 | 7.4 | — | — | 13.8 |
| Metals and mining | 3.4 | 8.3 | 0.2 | — | 11.9 |
| Paper | — | 11.1 | — | 0.2 | 11.3 |
| Entertainment/hotels | 6.2 | 0.4 | 1.1 | — | 7.7 |
| Collateralized loan obligations | 4.9 | 0.1 | — | — | 5.0 |
| Business services | — | 4.0 | 0.2 | — | 4.2 |
| Agency residential mortgage-backed securities | 1.3 | — | — | — | 1.3 |
| Packaging | — | 1.0 | — | — | 1.0 |
| Other | 15.9 | 0.2 | 0.2 | — | 16.3 |
| Total fixed maturities, available for sale | $1,543.6 | $716.9 | $55.0 | $24.3 | $2,339.8 |

90

Our investment strategy is to manage, over a sustained period and within acceptable parameters of quality and risk, capital efficiency through active strategic asset allocation and investment management. Accordingly, we may sell securities at a gain or a loss to enhance the projected total return of the portfolio as market opportunities change, to reflect changing perceptions of risk, or to better match certain characteristics of our investment portfolio with the corresponding characteristics of our insurance liabilities.

### INVESTMENTS IN VARIABLE INTEREST ENTITIES

The following table provides supplemental information about the revenues and expenses of the VIEs which have been consolidated in accordance with authoritative guidance, after giving effect to the elimination of our investment in the VIEs and investment management fees earned by a subsidiary of the Company (dollars in millions):

| Revenues: | Three months ended June 30, 2025 | 2024 | Six months ended June 30, 2025 | 2024 |
| --- | ---: | ---: | ---: | ---: |
| Net investment income – policyholder and other special-purpose portfolios | $7.3 | $11.9 | $14.8 | $25.9 |
| Fee revenue and other income | 0.9 | 0.7 | 2.4 | 1.6 |
| Total revenues | 8.2 | 12.6 | 17.2 | 27.5 |
| Expenses: |  |  |  |  |
| Interest expense | 5.9 | 9.8 | 13.7 | 21.7 |
| Other operating expenses | 1.3 | 0.4 | 2.3 | 0.9 |
| Total expenses | 7.2 | 10.2 | 16.0 | 22.6 |
| Income before net investment losses and income taxes | 1.0 | 2.4 | 1.2 | 4.9 |
| Net investment losses | (0.9) | (2.1) | (4.4) | (5.7) |
| Income (loss) before income taxes | $0.1 | $0.3 | $(3.2) | $(0.8) |

91

#### Supplemental Information on Investments Held by VIEs

The following table summarizes the carrying values and gross unrealized losses of the investments held by the VIEs by category as of June 30, 2025 (dollars in millions):

|  | Carrying value | Percent of fixed maturities | Gross unrealized losses | Percent of gross unrealized losses |
| --- | ---: | ---: | ---: | ---: |
| Technology | $51.0 | 13.5% | $0.3 | 12.3% |
| Brokerage | 44.7 | 11.9 | 0.1 | 5.7 |
| Healthcare/pharmaceuticals | 33.2 | 8.8 | 0.4 | 14.5 |
| Food/beverage | 28.3 | 7.5 | — | 1.9 |
| Cable/media | 25.9 | 6.9 | 0.4 | 15.3 |
| Chemicals | 25.2 | 6.7 | 0.4 | 14.0 |
| Building materials | 23.2 | 6.2 | 0.1 | 4.3 |
| Business services | 16.6 | 4.4 | 0.1 | 3.5 |
| Transportation | 16.2 | 4.3 | 0.1 | 2.1 |
| Utilities | 15.3 | 4.1 | 0.2 | 7.0 |
| Paper | 13.7 | 3.6 | 0.1 | 2.8 |
| Insurance | 13.3 | 3.5 | — | 1.9 |
| Aerospace/defense | 13.0 | 3.4 | 0.1 | 2.0 |
| Capital goods | 12.4 | 3.3 | 0.1 | 1.9 |
| Autos | 9.1 | 2.4 | — | 1.3 |
| Consumer products | 8.8 | 2.3 | 0.1 | 2.6 |
| Entertainment/hotels | 4.5 | 1.2 | — | 0.4 |
| Retail | 4.4 | 1.2 | 0.1 | 3.4 |
| Packaging | 4.3 | 1.2 | — | 0.4 |
| Energy | 3.9 | 1.0 | — | 0.1 |
| Other | 9.9 | 2.6 | — | 2.6 |
| Total | $376.9 | 100.0% | $2.6 | 100.0% |

The following table sets forth the amortized cost and estimated fair value of those investments held by the VIEs with unrealized losses at June 30, 2025, by contractual maturity. Actual maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without penalties.

*(Dollars in millions)*

|  | Amortized cost | Estimated fair value |
| --- | ---: | ---: |
| Due in one year or less | $1.5 | $1.5 |
| Due after one year through five years | 164.2 | 160.5 |
| Due after five years through ten years | 96.1 | 94.9 |
| Total | $261.8 | $256.9 |

92

The following summarizes the investments held by the VIEs sold at a loss during the first six months of 2025 which had been continuously in an unrealized loss position exceeding 20 percent of the amortized cost basis prior to the sale for the period indicated (dollars in millions):

|  | Number of issuers | At date of sale Amortized cost | Fair value |
| --- | ---: | ---: | ---: |
| Less than 6 months prior to sale | 1 | $0.6 | $0.4 |
| Greater than or equal to 6 months and less than 12 months prior to sale | 6 | 4.6 | 2.6 |
|  |  | $5.2 | $3.0 |

There were no investments held by the VIEs rated below-investment grade not deemed to have credit losses which had been continuously in an unrealized loss position exceeding 20 percent of the cost basis as of June 30, 2025.

### NEW ACCOUNTING STANDARDS

See "Recently Adopted Accounting Standards" and "Recently Issued Accounting Standards" in Note 1 to the Consolidated Financial Statements (unaudited) for a discussion of recently adopted and issued accounting standards.

## Market risk

As filed, 349 characters.

Our market risks, and the ways we manage them, are summarized in "Management's Discussion and Analysis of Financial Condition and Results of Operations", included in our Annual Report on Form 10-K for the year ended December 31, 2024. There have been no material changes in the first six months of 2025 to such risks or our management of such risks.

## Controls and procedures

As filed, 1,430 characters.

*Evaluation of Disclosure Controls and Procedures.* CNO's management, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of CNO's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the "Exchange Act")). Based on its evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2025, CNO's disclosure controls and procedures were effective to ensure that information required to be disclosed by CNO in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

*Changes to Internal Control Over Financial Reporting.* There were no changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the three months ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 456 characters.

CNO and its businesses are subject to a number of risks including general business and financial risks. Any or all of such risks could have a material adverse effect on the business, financial condition or results of operations of CNO. Refer to "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 for further discussion of such risk factors. There have been no material changes from such previously disclosed risk factors.

Filed Aug 6, 2025.
Source: SEC EDGAR, the filing index for accession 0001224608-25-000045. Last ingested by Listed: Nov 14, 2026, 19:45 ET. No prices; not investment advice.
